Detalhe da pesquisa
1.
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
Clin Exp Rheumatol
; 41(11): 2286-2297, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37404160
2.
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis.
Rheumatology (Oxford)
; 61(8): 3257-3268, 2022 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34864911
3.
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
Ann Rheum Dis
; 80(3): 312-320, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33272960
4.
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
Rheumatol Ther
; 9(2): 521-539, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34970731
5.
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
Rheumatol Ther
; 8(2): 903-919, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33913086